These observations also suggest that the application of glutamine antagonists and LAT1 inhibitors may overcome the immune suppressive tumor microenvironment through the downregulation of PD-L1 or reduce the uptake of immunosuppressive amino acid metabolites into NK or T cells. The gene discussed is SLC7A5; the disease is neoplasm.